Dietary management of adults with IBD—the emerging role of dietary therapy
Historically, dietitians played a minor part in the management of inflammatory bowel disease
(IBD), including Crohn's disease and ulcerative colitis. Patients were commonly referred for …
(IBD), including Crohn's disease and ulcerative colitis. Patients were commonly referred for …
The intestinal tissue homeostasis–the role of extracellular matrix remodeling in inflammatory bowel disease
JH Mortensen, M Lindholm, LL Langholm… - Expert Review of …, 2019 - Taylor & Francis
Introduction: Extracellular matrix (ECM) remodeling of the intestinal tissue is important in
inflammatory bowel disease (IBD) due to the extensive mucosal remodeling. There are still …
inflammatory bowel disease (IBD) due to the extensive mucosal remodeling. There are still …
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3 …
Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an
earlier phase 2 induction study, etrolizumab significantly improved clinical remission …
earlier phase 2 induction study, etrolizumab significantly improved clinical remission …
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled …
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In an earlier
phase 2 induction study, etrolizumab significantly improved clinical remission relative to …
phase 2 induction study, etrolizumab significantly improved clinical remission relative to …
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 …
S Danese, JF Colombel, M Lukas… - The lancet …, 2022 - thelancet.com
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis
1.1. Aim The overarching aim of ECCO is to improve the care of patients with IBD through
the development of guidelines, education and research. Current evidence is fundamental in …
the development of guidelines, education and research. Current evidence is fundamental in …
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase …
S Vermeire, PL Lakatos, T Ritter, S Hanauer… - The Lancet …, 2022 - thelancet.com
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease
SR Brown, NS Fearnhead, OD Faiz… - Colorectal …, 2018 - Wiley Online Library
Aim There is a requirement of an expansive and up to date review of surgical management
of inflammatory bowel disease (IBD) that can dovetail with the medical guidelines produced …
of inflammatory bowel disease (IBD) that can dovetail with the medical guidelines produced …
Hookworm-derived metabolites suppress pathology in a mouse model of colitis and inhibit secretion of key inflammatory cytokines in primary human leukocytes
P Wangchuk, C Shepherd, C Constantinoiu… - Infection and …, 2019 - Am Soc Microbiol
Iatrogenic hookworm therapy shows promise for treating disorders that result from a
dysregulated immune system, including inflammatory bowel disease (IBD). Using a murine …
dysregulated immune system, including inflammatory bowel disease (IBD). Using a murine …
Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network …
J Gao, R Nie, Y Chen, W Yang, Q Ren - Medicine, 2023 - journals.lww.com
Background: Biological agents are commonly used for the first-line treatment of ulcerative
colitis (UC). However, small-molecule drugs and microbiome therapies are now being used …
colitis (UC). However, small-molecule drugs and microbiome therapies are now being used …